Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff-Reference-Cited by-同舟云学术

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

Published:2014-03-25 Issue:10 Volume:20 Page:2805-2813
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Duchnowska Renata,Sperinde Jeff,Chenna Ahmed,Haddad Mojgan,Paquet Agnes,Lie Yolanda,Weidler Jodi M.,Huang Weidong,Winslow John,Jankowski Tomasz,Czartoryska-Arłukowicz Bogumiła,Wysocki Piotr J.,Foszczyńska-Kłoda Małgorzata,Radecka Barbara,Litwiniuk Maria M.,Żok Jolanta,Wiśniewski Michał,Zuziak Dorota,Biernat Wojciech,Jassem Jacek

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. p95HER2 expression in HER2‐positive breast cancer with primary resistance;Precision Medical Sciences;2024-04-04

2. Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer;Journal of Clinical Investigation;2023-07-17

3. A Review and Meta-analysis on Trastuzumab Resistance in Patients with HER2+ Breast Cancer;Mini-Reviews in Medicinal Chemistry;2023-06

4. Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects;Cancer Research;2022-05-03

5. Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer;Clinical Cancer Research;2021-08-11